Celcuity’s (CELC) “Buy” Rating Reiterated at HC Wainwright

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $27.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 48.68% from the company’s current price.

Separately, Stifel Nicolaus initiated coverage on shares of Celcuity in a research report on Thursday, February 22nd. They issued a “buy” rating and a $40.00 price target on the stock.

Celcuity Stock Up 3.7 %

CELC opened at $18.16 on Thursday. The company has a current ratio of 11.15, a quick ratio of 11.15 and a debt-to-equity ratio of 0.39. Celcuity has a 1-year low of $8.39 and a 1-year high of $18.95. The company has a market capitalization of $439.47 million, a PE ratio of -6.65 and a beta of 0.74. The firm’s 50 day simple moving average is $16.20 and its two-hundred day simple moving average is $13.51.

Institutional Trading of Celcuity

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Celcuity by 3.7% during the 4th quarter. Vanguard Group Inc. now owns 820,776 shares of the company’s stock valued at $11,959,000 after purchasing an additional 29,181 shares during the period. Perceptive Advisors LLC purchased a new position in Celcuity during the fourth quarter valued at $21,583,000. Barclays PLC grew its stake in Celcuity by 652.8% during the fourth quarter. Barclays PLC now owns 24,021 shares of the company’s stock valued at $350,000 after acquiring an additional 20,830 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Celcuity by 36.1% during the fourth quarter. Nuveen Asset Management LLC now owns 32,441 shares of the company’s stock valued at $473,000 after acquiring an additional 8,603 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in Celcuity by 12.0% during the fourth quarter. Royal Bank of Canada now owns 18,909 shares of the company’s stock valued at $276,000 after acquiring an additional 2,020 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.